WebOct 5, 2024 · Structure-activity relationship study of THZ531 derivatives enables the discovery of BSJ-01-175 as a dual CDK12/13 covalent inhibitor with efficacy in Ewing … WebApr 20, 2024 · Structure-activity relationship study of THZ531 derivatives enables the discovery of BSJ-01-175 as a dual CDK12/13 covalent inhibitor with efficacy in Ewing sarcoma. Baishan Jiang Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, 02115, USA; Department of Biological Chemistry …
7NXJ - RCSB
WebBSJ-01-175 is a potent and selective CDK12/13 covalent inhibitor. BSJ-01-175 demonstrates exquisite selectivity, potent inhibition of RNA polymerase II phosphorylation, and downregulation of CDK12-targeted genes in cancer cells. WebJan 15, 2024 · BSJ-01-175. CAS No. : 2227392-55-2. Biological Activity:BSJ-01-175 is a potent and selective CDK12/13 covalent inhibitor. BSJ-01-175 demonstrates exquisite selectivity, potent inhibition of RNA polymerase II phosphorylation, and downregulation of CDK12-targeted genes in cancer cells. Research Area:Cancer. Targets:CDK cheltenham radiotherapy
Current progress and novel strategies that target CDK12 …
WebBSJ-01-175. CAT NO. : 2227392-55-2. CAS NO. : 2227392-55-2. Inquiry. Quick Links. Online Inquiry; Featured Products; Events; Webinars; About Us; Time to Go GMP? kg to MT scale Cleanroom Class 100 to Class 100,000 HPAPI production with OEL . 1 μg/m³ Read More. Publication citing WebJan 1, 2024 · Recently, Jiang et al. discovered BSJ-01-175, a new THZ531 derivative, showing strong anti-proliferation ability against Ewing's sarcoma. [129] Download : Download high-res image (652KB) Download : Download full-size image; Fig. 3. (a) CDK12 inhibitor monotherapy strongly inhibited the suppression of cancer cell proliferation and … WebApr 20, 2024 · Structure-activity relationship study of THZ531 derivatives enables the discovery of BSJ-01-175 as a dual CDK12/13 covalent inhibitor with efficacy in Ewing … cheltenham racing tv coverage